GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Shares Outstanding (EOP)

Fennec Pharmaceuticals (TSX:FRX) Shares Outstanding (EOP) : 27.42 Mil (As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Fennec Pharmaceuticals's shares outstanding for the quarter that ended in Sep. 2024 was 27.42 Mil.

Fennec Pharmaceuticals's quarterly shares outstanding increased from Jun. 2024 (27.33 Mil) to Sep. 2024 (27.42 Mil). It means Fennec Pharmaceuticals issued new shares from Jun. 2024 to Sep. 2024 .

Fennec Pharmaceuticals's annual shares outstanding increased from Dec. 2022 (26.36 Mil) to Dec. 2023 (27.03 Mil). It means Fennec Pharmaceuticals issued new shares from Dec. 2022 to Dec. 2023 .


Fennec Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Fennec Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Shares Outstanding (EOP) Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.90 26.00 26.01 26.36 27.03

Fennec Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.41 27.03 27.11 27.33 27.42

Competitive Comparison of Fennec Pharmaceuticals's Shares Outstanding (EOP)

For the Biotechnology subindustry, Fennec Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Shares Outstanding (EOP) falls into.



Fennec Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Fennec Pharmaceuticals  (TSX:FRX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Fennec Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Robert Christopher Andrade Senior Officer
Rostislav Christov Raykov Director, Senior Officer
Adrian J. Haigh Senior Officer
Chris Anigeron Rallis Director
Khalid Islam Director

Fennec Pharmaceuticals Headlines

From GuruFocus

Forest Road Letter to Stockholders

By Business Wire Business Wire 06-01-2021

Beachbody CEO Letter to Forest Road Shareholders

By Business Wire Business Wire 06-09-2021